---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000066"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-06-22T20:43:01+00:00"
generated_at: "2026-06-22T20:44:12.688716+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FDA grants Breakthrough Therapy Designation for Praxis Precision Medicines' elsunersen for SCN2A-DEE

## Summary
- FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide for seizures in SCN2A Developmental and Epileptic Encephalopathy.
- BTD expedites development and regulatory review; supported by positive topline data from EMBRAVE Part A trial.
- EMBRAVE Part A was a randomized, sham-controlled Phase 1/2 study in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.
- The designation covers Gain of Function variants in SCN2A.

## SEC filing metadata
- accession: 0001689548-26-000066
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-06-22T20:43:01+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/0001689548-26-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000066/prax-20260622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000066
- JSON: https://secwatch.observer/filing/0001689548-26-000066.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.